Business

Moderna and Merck shares surge after melanoma vaccine success

Financial Post · August 19, 2026 at 12:29 p.m.

A personalized vaccine developed by Moderna Inc. and Merck & Co.

Inc. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology .

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

This story in other outlets

Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

CBC World · 2 h ago

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

The Globe and Mail · 6 h ago

Moderna and Merck shares surge after melanoma vaccine success

This story in other outlets

Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

More from Financial Post

Array Promotes Chad Hoffman to President and Lindsay Duprey to Chief Operating Officer

AMSYS and SEYOND Announce Strategic Partnership to Advance Spatial Intelligence and Operational Digital Twins

The Grid Queue Runs Five Years. This Equipment Ships on a Truck.

‘Where do I go?’ — Moneris sale sparking concerns over fees and transparency

More in Business

Array Promotes Chad Hoffman to President and Lindsay Duprey to Chief Operating Officer

AMSYS and SEYOND Announce Strategic Partnership to Advance Spatial Intelligence and Operational Digital Twins

The Grid Queue Runs Five Years. This Equipment Ships on a Truck.

‘Where do I go?’ — Moneris sale sparking concerns over fees and transparency

The Federal Bridge Corporation Limited’s ‘A+’ credit ratings affirmed by S&P Global Ratings; outlook remains Positive

Media Advisory: Ottawa Community Housing to Break Ground on 159 New Affordable Homes in Lowertown